The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 10 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Assertion Supported
Acker: Biotech stocks fell 64% absolute and 75% relative in 2021-2022
“Between February of 2021 and June of 2022, we had one of the worst bear markets in biotech sector in history. So on an absolute basis, these stocks declined 64% and relative to the health care sector, they traded down about 75%.”
Andy Acker Oct 6, 2022 ▶ 21:45 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: Over 200 biotech companies traded below cash after the 2022 crash
“Now, after that, you get to a point where actually 200 different companies were trading below the levels of cash on their balance sheet. That's highly unusual. We've never seen that before, even going back to The global financial crisis and the bear market, th…”
Andy Acker Oct 6, 2022 ▶ 22:25 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: Small and mid-cap biotechs develop over 60% of new medicines
“Over 60% of the new medicines that reach the market today were developed by small and mid cap biotech companies.”
Andy Acker Oct 6, 2022 ▶ 35:36 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: Human Genome Sequencing Takes Hours for Hundreds of Dollars
“Now we can sequence a human genome literally in hours, and we can do it for hundreds of dollars.”
Andy Acker Oct 6, 2022 ▶ 5:55 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: US Drug Approvals Rose Over 100% Across Five Years
“In the last five years, there have been 256 new medicines approved in the United States, and that's up over a hundred percent from where we were just 10 years ago.”
Andy Acker Oct 6, 2022 ▶ 9:02 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: 90% of drugs entering clinical trials never reach the market
“If you look at the industry over the last multiple decades, 90% of the products that begin human clinical testing never make it all the way to market.”
Andy Acker Oct 6, 2022 ▶ 10:45 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: The industry average success rate for Phase 3 trials is 50%
“And if you think about the industry statistics for a phase three study, the average success rate of the industry is about 50%.”
Andy Acker Oct 6, 2022 ▶ 11:51 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: Physician prescriptions determine 80% of healthcare spending
“So the physicians write the prescriptions that affect 80% of healthcare spending.”
Andy Acker Oct 6, 2022 ▶ 16:34 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: Biotech experienced eleven bear markets of over 20% since 2006
“Back when the SMP select biotech index and the XBI, which is an ETF that tracks that broad biotech index that was created back in 2006. So about 16 years ago, since that time before the recent bear market, and we'll get to that, but there were 11 effectively b…”
Andy Acker Oct 6, 2022 ▶ 19:28 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Assertion Supported
Acker: Pfizer needs to acquire $25 billion in revenue by 2030
“And even just Pfizer alone has said that they need to make acquisitions to acquire twenty five billion dollars of revenue by the end of 2030.”
Andy Acker Oct 6, 2022 ▶ 47:40 Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 700 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.